News
12-21-2009, 07:40 AM
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.
More... (http://www.news-medical.net/news/20091221/Teva-Pharmaceutical-Industries-OncoGenex-Pharmaceuticals-announce-collaboration-in-cancer-therapy.aspx)
More... (http://www.news-medical.net/news/20091221/Teva-Pharmaceutical-Industries-OncoGenex-Pharmaceuticals-announce-collaboration-in-cancer-therapy.aspx)